Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

May 17, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

Witnessing rays of hope as the first Ebola treatment wins approval by FDA

Is the pandemic interfering with the treatment for other diseases?

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth
  • BiotechToday
  • World

New Acyl CoA synthetase 4 inhibitor reduces breast and prostate tumour growth

bioxone October 19, 2020October 19, 2020

Rohit Bhattacharjee, Amity University Kolkata

Acyl CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme A family that takes part in arachidonic acid metabolism and steroidogenesis. ACSL4 is involved in tumour aggressiveness in breast and prostate tumours through various signal transduction pathways regulation. A well-validated ACSL4 inhibitor, however, has not been reported that hinders the entire exploration of the promising target and its therapeutic application on cancer and steroidogenesis inhibition. But in this regard, PRGL493 is identified as a homology model for ACSL4 and docking based virtual screening. Then it was chemically characterized through NMR and mass spectroscopy.

The inhibitory activity was demonstrated through the inhibition of arachidonic acid transformation into arachidonoyl CoA using recombinant enzyme and cellular models. The compound blocked cell proliferation and tumour growth in both breast and prostate cellular and animal models and sensitized the tumour cells to chemotherapeutic and hormonal treatment. Additionally, PRGL493 inhibited de novo steroid synthesis in testis and adrenal cells, in a mouse model and prostate tumour cells. This work proves the concept for potential application of PRGL493 in clinical practice. Moreover, they might prove keys to therapies aiming at control of tumour growth and drug resistance in tumours that express Acyl CoA synthetase 4 (ACSL4) and rely on steroid synthesis.

Also read: Efficient and cost-effective Bacterial mRNA sequencing causing ribosomal RNA depletion

Source- 

Castillo, A.F., Orlando, U.D., Maloberti, P.M. et al. New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumour growth, therapeutic resistance and steroidogenesis. Cell. Mol. Life Sci. (2020). https://doi.org/10.1007/s00018-020-03679-5

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged ACSL4 arachidonic acid breast tumour chemotherapeutics de novo synthesis hormonal treatment inhibitor mass spectroscopy NMR PRGL493 prostate steroidogenesis

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Is the pandemic interfering with the treatment for other diseases?

bioxone October 19, 2020

Camelia Bhattacharyya, Amity University Kolkata The pandemic, that is, the COVID-19 pandemic hit the world all of a sudden, changing infection rates or rather increasing it every day without leaving the world to think of the ways to fight with the unknown enemy, the virus. This created a lot of panic at the beginning of […]

other diseases

Related Post

  • BiotechToday
  • World

The device helps individuals with paralysis in communication

bioxone July 18, 2021July 18, 2021

Shrestha Dutta, Amity University Kolkata Scientists have developed brain waves of a paralyzed man who is unable to speak to form words from his contemplations onto a computer.  A group of scientists carried out research and the results of the same were published on 15th July in the New England Journal of Medicine. According to […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • FEATURED
  • Latest
  • World

The panacea to prevent all forms of Epileptic seizures?-Mozart may have the answer. Read on to find out.

bioxone September 14, 2020September 14, 2020

–Yashraj Singh, Amity University Kolkata Epilepsy is one of the most misinterpreted serious Neurological diseases of all time and surprisingly the most demographically(in the population) prevalent. There are various forms of epileptic seizures of which the tonic-clonic seizures(involuntary muscular contractions) being the most traumatizing and rarest of all. At least in India, people have blatantly […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

A Study on 200 million-year cycle of Earth’s Magnetic Field

BioTech Today August 21, 2021August 20, 2021

Agrima Bhatt, Rajasthan University Geomagnetic field of the earth The magnetic field of the Earth is roughly a magnetic dipole, with the magnetic field S pole at the geographic north pole and the magnetic field N pole near the geographic south pole. A magnetic field is endlessly long, however, it starts to decrease as it […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy